Potent Neutralizing Activity of Polyclonal Equine Antibodies against Omicron SARS-CoV-2

  1. J. Luczkowiak
  2. P. Radreau
  3. L. Nguyen
  4. N. Labiod
  5. F. Lasala
  6. C.H. Herbreteau
  7. R. Delgado

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Using a polyclonal approach of equine anti-SARS-CoV-2 F(ab’)2 antibodies we have achieved a high level of neutralizing potency against all SARS-CoV-2 variants tested. Neutralization titers were in the range of 10 5 -10 6 IU/mL including Omicron: 111,403 UI/mL, which is 2-3 orders of magnitude what is normally achieved in response to SARS-CoV-2 infection and/or vaccination. The presence of high titers of a repertoire of antibodies targeting conserved epitopes in different regions of the spike protein could plausibly account for this remarkable breadth of neutralization. These results warrant the clinical investigation of anti-SARS-CoV-2 equine polyclonal F(ab’)2 antibodies as a novel therapeutic strategy against COVID-19

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2022.02.21.481341: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Ethicsnot detected.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    BHK-21 were transfected to express the SARS-CoV-2 S protein using Lipofectamine 3000 (Thermo Fisher Scientific, Madrid, Spain) and after 24h transfected cells were inoculated with a replication-deficient rVSV-luc pseudotype (MOI: 3-5) that contains firefly luciferase instead of the VSV-G open reading frame, rVSVΔG-luciferase (G*ΔG-luciferase; Kerafast).
    BHK-21
    suggested: ECACC Cat# 93120841, RRID:CVCL_2304)
    After the incubation time, 20,000 Vero E6 cells were seeded onto the virus-plasma mixture and incubated in a 37ºC for 24h.
    Vero E6
    suggested: None
    Recombinant DNA
    SentencesResources
    EBOV strain Makona GP (GeneBank: KM2330102.1) was synthesized and cloned into pcDNA3.1 by GeneArt® technology.
    pcDNA3.1
    suggested: RRID:Addgene_79663)
    Software and Algorithms
    SentencesResources
    Neutralizing titer 50 (NT50) and 95% confidence intervals (95% CI) were calculated using a nonlinear regression model fit with settings for log inhibitor versus normalized response curves, in GraphPad Prism v8.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2022.02.21.481341 on bioRxiv